Cymabay Therapeu Stock Today
CBAY Stock | USD 32.46 0.01 0.03% |
Performance13 of 100
| Odds Of DistressLess than 9
|
Cymabay Therapeu is trading at 32.46 as of the 18th of March 2024; that is 0.03 percent increase since the beginning of the trading day. The stock's open price was 32.45. Cymabay Therapeu has less than a 9 % chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. Equity ratings for Cymabay Therapeu are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 17th of February 2024 and ending today, the 18th of March 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of February 2014 | Category Healthcare | Classification Health Care |
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. The company has 114.78 M outstanding shares of which 5.85 M shares are currently shorted by private and institutional investors with about 0.84 trading days to cover. More on Cymabay Therapeu
Moving against Cymabay Stock
0.88 | AKAN | Akanda Corp Report 6th of May 2024 | PairCorr |
0.81 | VALN | Valneva SE ADR Earnings Call This Week | PairCorr |
0.81 | MYMD | MyMD Pharmaceuticals Report 29th of March 2024 | PairCorr |
0.7 | IMMX | Immix Biopharma Report 25th of March 2024 | PairCorr |
0.54 | FLGC | Flora Growth Corp Report 29th of March 2024 | PairCorr |
0.54 | ABCL | Abcellera BiologicsInc Financial Report 2nd of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Report 21st of March 2024
Cymabay Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cymabay Therapeu's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cymabay Therapeu or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO and President and Director | Harold Wart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Thematic Idea | Disruptive Technologies (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Disruptive Technologies, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation Analysts covering Cymabay Therapeu report their recommendations after researching Cymabay Therapeu's financial statements, talking to executives and customers, or listening in on Cymabay Therapeu's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Cymabay Therapeu. The Cymabay consensus assessment is calculated by taking the average forecast from all of the analysts covering Cymabay Therapeu. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength Based on the key indicators related to Cymabay Therapeu's liquidity, profitability, solvency, and operating efficiency, Cymabay Therapeu is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. Financial strength of Cymabay Therapeu is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cymabay Therapeu's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Cymabay Therapeu's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cymabay Therapeu's financial leverage. It provides some insight into what part of Cymabay Therapeu's total assets is financed by creditors.
|
Cymabay Therapeu (CBAY) is traded on NASDAQ Exchange in USA. It is located in 7601 Dumbarton Circle, Fremont, CA, United States, 94555 and employs 101 people. Cymabay Therapeu is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.72 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cymabay Therapeu's market, we take the total number of its shares issued and multiply it by Cymabay Therapeu's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cymabay Therapeu conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 114.78 M outstanding shares of which 5.85 M shares are currently shorted by private and institutional investors with about 0.84 trading days to cover.
Cymabay Therapeu currently holds about 153.42 M in cash with (72.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81.
Check Cymabay Therapeu Probability Of Bankruptcy
Ownership AllocationCymabay Therapeu retains a total of 114.78 Million outstanding shares. The majority of Cymabay Therapeu outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cymabay Therapeu to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cymabay Therapeu. Please pay attention to any change in the institutional holdings of Cymabay Therapeu as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Cymabay Ownership Details
Cymabay Stock Price Odds Analysis
Based on a normal probability distribution, the odds of Cymabay Therapeu jumping above the current price in 90 days from now is about 9.15%. The Cymabay Therapeu probability density function shows the probability of Cymabay Therapeu stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Cymabay Therapeu has a beta of 0.7367 suggesting as returns on the market go up, Cymabay Therapeu average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Cymabay Therapeu will be expected to be much smaller as well. Additionally, the company has an alpha of 0.6443, implying that it can generate a 0.64 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Cymabay Therapeu to move above the current price in 90 days from now is about 9.15 (This Cymabay Therapeu probability density function shows the probability of Cymabay Stock to fall within a particular range of prices over 90 days) .
Cymabay Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Cymabay Therapeu that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cymabay Therapeu's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cymabay Therapeu's value.Instituion | Recorded On | Shares | |
Fmr Inc | 2023-12-31 | 3.1 M | |
State Street Corporation | 2023-12-31 | 2.8 M | |
Adage Capital Partners Gp Llc | 2023-12-31 | 2.6 M | |
Point72 Asset Management, L.p. | 2023-09-30 | 2.4 M | |
Geode Capital Management, Llc | 2023-12-31 | 2.4 M | |
Fred Alger Management, Llc | 2023-12-31 | 2 M | |
Cormorant Asset Management, Llc | 2023-12-31 | 1.8 M | |
Vestal Point Capital Lp | 2023-12-31 | 1.6 M | |
First Turn Management Llc | 2023-12-31 | 1.5 M | |
Venbio Select Advisor Llc | 2023-12-31 | 11.1 M | |
Blackrock Inc | 2023-12-31 | 9.6 M |
Cymabay Therapeu Historical Income Statement
Cymabay Therapeu Income Statement is one of the three primary financial statements used for reporting Cymabay's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Cymabay Therapeu revenue and expense. Cymabay Therapeu Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Cymabay Therapeu's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 19.9 M in 2024, despite the fact that Operating Income is likely to grow to (96.6 M). View More FundamentalsCymabay Stock Against Markets
Picking the right benchmark for Cymabay Therapeu stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cymabay Therapeu stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cymabay Therapeu is critical whether you are bullish or bearish towards Cymabay Therapeu at a given time. Please also check how Cymabay Therapeu's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cymabay Therapeu without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Commodity Channel Now
Commodity ChannelUse Commodity Channel Index to analyze current equity momentum |
All Next | Launch Module |
Cymabay Therapeu Corporate Directors
Cymabay Therapeu corporate directors refer to members of a Cymabay Therapeu board of directors. The board of directors generally takes responsibility for the Cymabay Therapeu's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Cymabay Therapeu's board members must vote for the resolution. The Cymabay Therapeu board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.Caroline Loewy | Director | Profile | |
Paul Truex | Director | Profile | |
Robert Wills | Director | Profile | |
Kurt Emster | Independent Director | Profile |
How to buy Cymabay Stock?
Before investing in Cymabay Therapeu, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Cymabay Therapeu. To buy Cymabay Therapeu stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Cymabay Therapeu. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Cymabay Therapeu stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Cymabay Therapeu stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Cymabay Therapeu stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Cymabay Therapeu, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Cymabay Stock please use our How to Invest in Cymabay Therapeu guide.
Already Invested in Cymabay Therapeu?
The danger of trading Cymabay Therapeu is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Cymabay Therapeu is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Cymabay Therapeu. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Cymabay Therapeu is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Cymabay Therapeu offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cymabay Therapeu's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cymabay Therapeu Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cymabay Therapeu Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cymabay Therapeu. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Cymabay Stock please use our How to Invest in Cymabay Therapeu guide.Note that the Cymabay Therapeu information on this page should be used as a complementary analysis to other Cymabay Therapeu's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Cymabay Stock analysis
When running Cymabay Therapeu's price analysis, check to measure Cymabay Therapeu's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cymabay Therapeu is operating at the current time. Most of Cymabay Therapeu's value examination focuses on studying past and present price action to predict the probability of Cymabay Therapeu's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cymabay Therapeu's price. Additionally, you may evaluate how the addition of Cymabay Therapeu to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Cymabay Therapeu's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cymabay Therapeu. If investors know Cymabay will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cymabay Therapeu listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 0.293 | Return On Assets (0.22) | Return On Equity (0.64) |
The market value of Cymabay Therapeu is measured differently than its book value, which is the value of Cymabay that is recorded on the company's balance sheet. Investors also form their own opinion of Cymabay Therapeu's value that differs from its market value or its book value, called intrinsic value, which is Cymabay Therapeu's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cymabay Therapeu's market value can be influenced by many factors that don't directly affect Cymabay Therapeu's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cymabay Therapeu's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cymabay Therapeu is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cymabay Therapeu's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.